Protalix BioTherapeutics, Inc.

PLXAMEXHealthcare● Active

$1.96

$-0.03(-1.51%)

Market Cap$157920418

P/E Ratio—

52W High$3.19

52W Low$1.32

Avg Volume867K

Open$1.97

Beta0.01

Cash on Hand Financials Revenue

Protalix BioTherapeutics, Inc. (PLX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

PLX · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$30.3M▼ -13.1% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$14.7M

cashAndCashEquivalents

Short-Term Investments

$15.6M

shortTermInvestments

YoY Change vs Prior Year

-13.1%

vs prior fiscal year

Latest Quarter

$51.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$30.3MCash on Hand

Total Debt$8.3MTotal Debt

Net Cash / Net Debt+$22.0MNet Cash Position

Cash vs Debt Ratio

Cash 78%Protalix BioTherapeutics, Inc. cash as % of market cap: 19.17%% · MCap $0BDebt 22%

Protalix BioTherapeutics, Inc. has a net cash position of $22.0M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$30.3M − $8.3M = +$22.0M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

PLX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

PLX cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$30.3M-13.1%

Dec 31, 2024FY$34.8M-21.8%

Dec 31, 2023FY$44.6M+100.9%

Dec 31, 2022FY$22.2M-43.1%

Dec 31, 2021FY$39.0M+1.1%

PLX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

PLX vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Protalix BioTherapeutics, Inc.YOU

PLX

$30.3M$158M19.2%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Protalix BioTherapeutics, Inc. (PLX) cash on hand as of December 31, 2025 is $30.3M, comprising $14.7M in cash and cash equivalents (CCE) plus $15.6M in short-term investments — reported as Protalix BioTherapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Protalix BioTherapeutics, Inc. cash reserves or cash position.

Protalix BioTherapeutics, Inc. annual cash on hand history shows decreased -13.1% in 2025: decreased -13.1% in 2025. Protalix BioTherapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Protalix BioTherapeutics, Inc. carries total debt of $8.3M against cash of $30.3M, resulting in a net cash position of +$22.0M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

PLX cash on hand · 5 questions

As of December 31, 2025, Protalix BioTherapeutics, Inc. (PLX) has $30,273,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $14,680,000 in cash and cash equivalents (CCE) plus $15,593,000 in short-term investments. Latest quarter (March 31, 2026): $51,794,000. Data sourced from the annual 10-K filing via FMP.

PLX cash on handPLX cash reservesPLX cash 2025how much cash does PLX have

▸ Source: FMP /balance-sheet-statement · US GAAP · Protalix BioTherapeutics, Inc. · Protalix BioTherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025